Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
about
Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activityFlavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitinationBRCA1 is an essential regulator of heart function and survival following myocardial infarctionDoxorubicin cardiomyopathyA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathJuvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult micePharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donorsA functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinityResearch progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicityDual Role of ROS as Signal and Stress Agents: Iron Tips the Balance in favor of Toxic EffectsThe Tumorigenic Roles of the Cellular REDOX Regulatory SystemsBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesExercise Prevention of Cardiovascular Disease in Breast Cancer SurvivorsGetting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyEfficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled TrialsRole of pregnane X receptor in chemotherapeutic treatmentNucleic acid aptamers: an emerging frontier in cancer therapyCardiac toxicity in cancer survivorsEvolving concepts in cancer therapy through targeting sphingolipid metabolismOxygen in human health from life to death--An approach to teaching redox biology and signaling to graduate and medical studentsThe effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancerPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironA review of current nanoparticle and targeting moieties for the delivery of cancer therapeuticsSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsA meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeTreatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsMitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specificDexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in MiceStructural and Functional Studies of QdtC: An N -Acetyltransferase Required for the Biosynthesis of dTDP-3-Acetamido-3,6-dideoxy-α- d -glucose † ‡Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compoundsOn the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugsCrystal structure of the glycosyltransferase SnogD from the biosynthetic pathway of nogalamycin in Streptomyces nogalaterDo AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.Mitoxantrone-Surfactant Interactions: A Physicochemical OverviewExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerMolecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaThe role of p53 in cancer drug resistance and targeted chemotherapyPET Metabolic Biomarkers for Cancer
P2860
Q21093334-611EFE3A-FE6E-4D70-9006-2508F65A8712Q21135010-C237069C-6642-4EF2-B46E-CB299F82798EQ23921930-FC6F5B42-3BD2-450E-A164-CC31B505C4D4Q24300290-C08A3017-99E7-4B0A-AFB3-63CB7004AFAEQ24606920-00165A73-D3F3-4BD5-B748-B9E40AD4248DQ24620548-29DF2884-A498-4FF5-AE71-622282B012DCQ24632487-FFBE4834-9EFC-4153-8013-3AC66252DA1DQ24646186-6CF88627-E091-471E-9FF5-04AB8AAE4E90Q24647984-52E8DD64-EBBC-4235-A96E-9D689EDF0B33Q26742059-2DB9BACC-1D90-4916-9476-DEC52236065EQ26744675-5B6EC067-43A9-4CC8-9AF2-78E1B6F52EDBQ26752455-07C53BCC-F3EF-4465-BCBD-1E03D5603977Q26774894-1E823582-1D90-43FC-AC6E-56734C54FE96Q26783705-9F4C2C8E-3A65-4A05-B5F4-5847F35F18F2Q26785410-C94FA95C-EFCE-4248-8E35-62BBCC696092Q26797138-C057238F-FA85-4FF9-A86C-CC24A4A7D36AQ26800140-1F22A696-7A81-43D8-8847-56A532B5AC55Q26827398-6A4C13EB-A124-4161-A3FA-74BD44A9FB80Q26849947-EB196267-9C8A-48A0-A71A-C0D3D282A1E2Q26851957-859A3728-F115-4067-89AA-0AABC036787EQ26863646-73CDC551-DFE2-4C88-B88D-1CAB3714D149Q26998478-5F2266A0-E034-4C75-927B-04C2B6F5C6B6Q26999300-FA91EB96-5BBE-4A87-B824-25C0B634E58FQ27004170-96ABD767-3366-4F1B-B676-0095C51A9B01Q27006569-A33A0E5D-17BC-423D-9863-8B3D3AFAEB62Q27007849-F5653C99-107E-480F-A525-DFF8BFD65524Q27024786-8A6B47B7-1B38-4B49-9035-D93B4257850CQ27025606-2FA2FD73-405C-487C-8779-5A00EC2EE02EQ27301261-8E7DC79B-E081-4853-9402-9ABC61A6C610Q27345163-2C56AD29-2D5F-4BC5-AEB3-5107616569A1Q27653643-8543286E-6AD3-4BA4-B9DE-38FA797657B5Q27678492-BE24904E-C2EF-40A6-A308-8674311DD541Q27679956-82E99E2D-B67F-4EBF-BA85-CC55B455A110Q27681762-B2A87186-6884-4E91-8DBE-6C7046035645Q27851686-B15DB230-E0B6-43F6-A24A-F9CBADAFC0DCQ28066259-D2D8D2C1-6995-4BBA-ABBC-469052069F29Q28066481-9E519604-6258-4978-8601-A1D1047B0196Q28072058-A65081E1-F870-4AEA-8CCB-82411C46AB36Q28072553-57A2D79D-CA39-400F-9F16-09A0B9BAF36AQ28074449-F914A0D7-B4F8-49D0-85C8-77C4EEE25B44
P2860
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@ast
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@en
type
label
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@ast
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@en
prefLabel
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@ast
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@en
P2093
P50
P3181
P356
P1476
Anthracyclines: molecular adva ...... or activity and cardiotoxicity
@en
P2093
P304
P3181
P356
10.1124/PR.56.2.6
P407
P577
2004-06-01T00:00:00Z